Key facts
- This page summarizes Leonard D. Schaeffer's Form 4 filing for scPharmaceuticals Inc. (SCPH).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Jun 2025, 16:42.
Leonard D. Schaeffer - 03 Jun 2025 Form 4 Insider Report for scPharmaceuticals Inc. (SCPH)
- Reporting relationship
- Director
- Issuer ticker
- SCPH
- Reported as of
- 03 Jun 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jun 2025, 16:42:07 UTC
- Prior SEC filing
- 28 Aug 2024
- Next SEC filing
- 07 Oct 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ John H. Tucker, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Leonard D. Schaeffer filed Form 4 for scPharmaceuticals Inc. (SCPH) on 05 Jun 2025.
Change
- Previous filing in this sequence was filed on 28 Aug 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001016369
Primary reporting owner
SCHAEFFER LEONARD D
- Relationship
- Director
- Address
- C/O SCPHARMACEUTICALS INC, 25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON
- Signature
- /s/ John H. Tucker, attorney-in-fact
- Signature date
- 05 Jun 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SCPH
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 03 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $3.85
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This stock option vests in full upon the earlier of (i) June 3, 2026, or (ii) the next annual meeting of the Issuer's stockholders.